Kenneth A. Tassey
Keine laufenden Positionen mehr
Profil
Kenneth A.
Tassey is the founder of Boston Therapeutics, Inc. which was founded in 2009.
He held the title of President & Chief Executive Officer in 2010 and President & Director from 2010 to 2014.
He also worked as President at LRN Corp.
from 2007 to 2009.
Ehemalige bekannte Positionen von Kenneth A. Tassey
| Unternehmen | Position | Ende |
|---|---|---|
| NANOMIX CORPORATION | Gründer | 30.06.2014 |
| Boston Therapeutics, Inc. /Old/ | Vorstandsvorsitzender | 01.11.2010 |
LRN Corp.
 LRN Corp. Miscellaneous Commercial ServicesCommercial Services LRN Corp. provides ethics and compliance knowledge solutions and advisory services. It offers integrated solutions, such as essential ethics and compliance, essential inspirational leadership, essential environmental and social responsibility, ethics and compliance management system, and education services. The company was founded by Dov L. Seidman in 1994 and is headquartered in Los Angeles, CA. | Präsident | 01.03.2009 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
LRN Corp.
LRN Corp. Miscellaneous Commercial ServicesCommercial Services LRN Corp. provides ethics and compliance knowledge solutions and advisory services. It offers integrated solutions, such as essential ethics and compliance, essential inspirational leadership, essential environmental and social responsibility, ethics and compliance management system, and education services. The company was founded by Dov L. Seidman in 1994 and is headquartered in Los Angeles, CA. | Commercial Services |
| Boston Therapeutics, Inc. /Old/ | Health Technology |
Boston Therapeutics, Inc.
 Boston Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Boston Therapeutics, Inc. is a pharmaceutical company, which engages in the development, manufacture, and commercialization of novel compounds based on complex carbohydrate chemistry. Its products are designed to help manage blood sugar, treat pre-diabetes, and diabetes related pathologies. Its drug candidates comprises of BTI320, BTI-410, and IPOXYN. The company was founded by David Platt and Kenneth A. Tassey Jr. on August 24, 2009 and is headquartered in Lawrence, MA. | Health Technology |
